IOVANCE BIOTHERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$123.58 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2019-02-28
- IOVANCE BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2017-12-31 was -$25.85M.
- IOVANCE BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2017-09-30 was -$22.15M.
- IOVANCE BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-12-31 was -$15.69M.
- IOVANCE BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-09-30 was -$68.21M.
- IOVANCE BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$123.58M.
- IOVANCE BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2017 was -$92.06M.
- IOVANCE BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2016 was -$102.35M.
- IOVANCE BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2015 was -$27.66M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 72 month | Net Income (Loss) Available to Common Stockholders, Basic 78 month |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | -$123.58M 10-K · filed 2019-02-28 | ||||||
| 2017-12-31 | -$25.85M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$48.00M derived: sum of 2 quarters · filed 2019-02-28 | -$92.06M 10-K · filed 2019-02-28 | ||||
| 2017-09-30 | -$22.15M 10-Q · filed 2017-11-02 | -$66.21M 10-Q · filed 2017-11-02 | |||||
| 2016-12-31 | -$15.69M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$83.90M derived: sum of 2 quarters · filed 2019-02-28 | -$102.35M 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | -$68.21M 10-Q · filed 2017-11-02 | -$86.66M 10-Q · filed 2017-11-02 | |||||
| 2015-12-31 | -$8.36M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$15.99M derived: sum of 2 quarters · filed 2018-03-12 | -$27.66M 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | -$7.63M 10-Q · filed 2016-11-04 | -$19.30M 10-Q · filed 2016-11-04 | |||||
| 2014-12-31 | -$12.04M 10-K · filed 2017-03-09 | -$12.03M 10-K · filed 2015-03-16 | |||||
| 2014-03-31 | -$2.26M 10-Q · filed 2014-05-14 | -$66.79M 10-Q · filed 2014-05-14 | |||||
| 2013-12-31 | -$33.84M 10-K · filed 2016-03-11 | -$33.84M 10-K · filed 2014-03-28 | -$64.53M 10-K · filed 2014-03-28 | ||||
| 2013-03-31 | -$1.05M 10-Q · filed 2014-05-14 | ||||||
| 2012-12-31 | -$3.31M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |